BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, Zenari L, Bonora E. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010;53:1341-1348. [PMID: 20369224 DOI: 10.1007/s00125-010-1720-1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17:562. [PMID: 27089331 DOI: 10.3390/ijms17040562] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
2 Aller de la Fuente R, Mora Cuadrado N, Tafur C, López Gómez JJ, Gómez de la Cuesta S, García Sánchez MC, Antolin Melero B, de Luis Román DA. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes. Endocrinología, Diabetes y Nutrición 2018;65:354-60. [DOI: 10.1016/j.endinu.2017.12.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Serra-planas E, Aguilera E, Castro L, Rodríguez R, Salinas I, Lucas A, Joaquín C, Puig R, Mauricio D, Puig-domingo M. Low prevalence of non-alcoholic fatty liver disease in patients with type 1 diabetes is associated with decreased subclinical cardiovascular disease: 在1型糖尿病患者中非酒精性脂肪性肝病的患病率较低与亚临床心血管疾病较少相关. Journal of Diabetes 2017;9:1065-72. [DOI: 10.1111/1753-0407.12539] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Regnell SE, Lernmark Å. Hepatic steatosis in type 1 diabetes. Rev Diabet Stud 2011;8:454-67. [PMID: 22580727 DOI: 10.1900/RDS.2011.8.454] [Cited by in Crossref: 59] [Cited by in F6Publishing: 24] [Article Influence: 5.9] [Reference Citation Analysis]
5 Aller R, Sigüenza R, Pina M, Laserna C, Antolín B, Burgueño B, Durà M, Izaola O, Primo D, de Luis DA. Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor. Endocrine 2020;68:557-63. [DOI: 10.1007/s12020-020-02268-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Wang LR, Zhou YF, Zhou YJ, Zhang SH, Liu WY, Wu SJ, Van Poucke S, Zheng MH. Elevation of plateletcrit increasing the risk of non-alcoholic fatty liver disease development in female adults: A large population-based study. Clin Chim Acta 2017;474:28-33. [PMID: 28866118 DOI: 10.1016/j.cca.2017.08.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Yoneda C, Ogino J, Matsuura H, Haruki T, Suzuki Y, Hashimoto N. Increased prevalence of diabetic complications in Japanese patients with type 1 diabetes and nonalcoholic fatty liver disease. Diabetol Int 2012;3:37-41. [DOI: 10.1007/s13340-011-0061-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. jour 2020;1:57-65. [DOI: 10.31146/1682-8658-ecg-170-10-57-65] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
9 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 28.4] [Reference Citation Analysis]
10 Sharma N, Sircar A, Anders HJ, Gaikwad AB. Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches. Arch Physiol Biochem 2020;:1-15. [PMID: 32223569 DOI: 10.1080/13813455.2020.1745851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785-801. [PMID: 32059982 DOI: 10.1016/j.jhep.2020.01.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 28.0] [Reference Citation Analysis]
12 Gerstein HC, Werstuck GH. Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. The Lancet Diabetes & Endocrinology 2013;1:71-8. [DOI: 10.1016/s2213-8587(13)70025-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
13 Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab 2021;12:20420188211055557. [PMID: 34840719 DOI: 10.1177/20420188211055557] [Reference Citation Analysis]
14 Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 2015;4:101-108. [PMID: 26005676 DOI: 10.3978/j.issn.2304-3881.2015.01.03] [Cited by in F6Publishing: 53] [Reference Citation Analysis]
15 Ziegler D, Strom A, Kupriyanova Y, Bierwagen A, Bönhof GJ, Bódis K, Müssig K, Szendroedi J, Bobrov P, Markgraf DF, Hwang JH, Roden M; GDS Group. Association of Lower Cardiovagal Tone and Baroreflex Sensitivity With Higher Liver Fat Content Early in Type 2 Diabetes.J Clin Endocrinol Metab. 2018;103:1130-1138. [PMID: 29267946 DOI: 10.1210/jc.2017-02294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
16 Li Z, Li Y, Zhang HX, Guo JR, Lam CWK, Wang CY, Zhang W. Mitochondria-Mediated Pathogenesis and Therapeutics for Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2019;63:e1900043. [PMID: 31199058 DOI: 10.1002/mnfr.201900043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
17 O'Leary JG, Levitsky J, Wong F, Nadim MK, Charlton M, Kim WR. Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant 2016;16:2516-31. [PMID: 26990924 DOI: 10.1111/ajt.13790] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
18 Stenvinkel P. Adiponectin in Chronic Kidney Disease: A Complex and Context Sensitive Clinical Situation. Journal of Renal Nutrition 2011;21:82-6. [DOI: 10.1053/j.jrn.2010.10.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
19 Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol 2014; 20(37): 13306-13324 [PMID: 25309067 DOI: 10.3748/wjg.v20.i37.13306] [Cited by in CrossRef: 118] [Cited by in F6Publishing: 116] [Article Influence: 14.8] [Reference Citation Analysis]
20 Fardet A, Martin JF, Chardigny JM. Thermal and refining processes, not fermentation, tend to reduce lipotropic capacity of plant-based foods. Food Funct 2011;2:483-504. [PMID: 21842076 DOI: 10.1039/c1fo10041f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
21 Shah RV, Allison MA, Lima JA, Abbasi SA, Mongraw-Chaffin M, Jerosch-Herold M, Ding J, Budoff MJ, Murthy VL. Liver steatosis and the risk of albuminuria: the multi-ethnic study of atherosclerosis. J Nephrol 2015;28:577-84. [PMID: 25712234 DOI: 10.1007/s40620-015-0177-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
22 Cipponeri E, Vitturi N, Mariano V, Boscari F, Galasso S, Crepaldi C, Fadini GP, Vigili de Kreutzenberg S, Marescotti MC, Iori E, Cavallin F, Sartori L, Baritussio A, Avogaro A, Bruttomesso D. Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes. J Endocrinol Invest 2019;42:1099-107. [DOI: 10.1007/s40618-019-01031-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Li G, Shi W, Hug H, Chen Y, Liu L, Yin D. Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. Biochem Med (Zagreb). 2012;22:92-99. [PMID: 22384523 DOI: 10.11613/bm.2012.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
24 Li AA, Ahmed A, Kim D. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gut Liver. 2020;14:168-178. [PMID: 31195434 DOI: 10.5009/gnl19069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
25 Motedayen M, Sarokhani D, Ghiasi B, Khatony A, Hasanpour Dehkordi A. Prevalence of Hypertension in Renal Diseases in Iran: Systematic Review and Meta-Analysis. Int J Prev Med 2019;10:124. [PMID: 31367287 DOI: 10.4103/ijpvm.IJPVM_522_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
26 Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5:7-13. [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
27 VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15:75-85. [PMID: 27218012 DOI: 10.1007/s11901-016-0295-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
28 Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010;5:2166-71. [PMID: 20724519 DOI: 10.2215/CJN.05050610] [Cited by in Crossref: 128] [Cited by in F6Publishing: 53] [Article Influence: 10.7] [Reference Citation Analysis]
29 Elkabbany ZA, Elbarbary NS, Ismail EA, Mohamed NA, Ragab D, Abdel Alem S, Ezzat YM, Maurice SS, Hashem NU. Transient elastography as a noninvasive assessment tool for hepatopathies of different etiology in pediatric type 1 diabetes mellitus. J Diabetes Complications 2017;31:186-94. [PMID: 27742550 DOI: 10.1016/j.jdiacomp.2016.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
30 Jia G, Di F, Wang Q, Shao J, Gao L, Wang L, Li Q, Li N. Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. PLoS One. 2015;10:e0142808. [PMID: 26566287 DOI: 10.1371/journal.pone.0142808] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
31 Li TT, Wang AP, Lu JX, Chen MY, Zhao CC, Tang ZH, Li LX, Jia WP. Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes. Diabetes Metab 2018;44:437-43. [PMID: 29631765 DOI: 10.1016/j.diabet.2018.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
32 Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174-1197. [PMID: 24002776 DOI: 10.1002/hep.26717] [Cited by in Crossref: 301] [Cited by in F6Publishing: 281] [Article Influence: 37.6] [Reference Citation Analysis]
33 Reinauer C, Reinehr T, Baechle C, Karges B, Seyfarth J, Foertsch K, Schebek M, Woelfle J, Roden M, Holl RW, Rosenbauer J, Meissner T. Relationship of Serum Fetuin A with Metabolic and Clinical Parameters in German Children and Adolescents with Type 1 Diabetes. Horm Res Paediatr. 2018;89:73-81. [PMID: 29207397 DOI: 10.1159/000484896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
34 Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138-1153. [PMID: 28314735 DOI: 10.1136/gutjnl-2017-313884] [Cited by in Crossref: 384] [Cited by in F6Publishing: 366] [Article Influence: 76.8] [Reference Citation Analysis]
35 Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clin Obes. 2014;4:243-253. [PMID: 25825857 DOI: 10.1111/cob.12068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
36 Afarideh M, Aryan Z, Ghajar A, Ganji M, Ghaemi F, Saadat M, Heidari B, Mechanick JI, Esteghamati A. Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. Prim Care Diabetes 2019;13:505-14. [PMID: 31054837 DOI: 10.1016/j.pcd.2019.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
37 Zeng J, Sun C, Sun WL, Chen GY, Pan Q, Yan SY, Xu ZJ, Chen YW, Fan JG. Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults on their health check-up. J Dig Dis. 2017;18:229-236. [PMID: 28296249 DOI: 10.1111/1751-2980.12465] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
38 Machado MV, Gonçalves S, Carepa F, Coutinho J, Costa A, Cortez-pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 2012;32:241-8. [DOI: 10.1111/j.1478-3231.2011.02623.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
39 Hsieh MH, Wu KT, Chen YY, Yang JF, Lin WY, Chang NC, Lin CY, Huang CK, Wang CL, Chuang HY, Lin SC, Hsu YK, Tsai YS, Chuang WL, Yu ML, Dai CY. Higher NAFLD fibrosis score is associated with impaired eGFR. J Formos Med Assoc. 2020;119:496-503. [PMID: 31353118 DOI: 10.1016/j.jfma.2019.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
40 Houlihan DD, Armstrong MJ, Davidov Y, Hodson J, Nightingale P, Rowe IA, Paris S, Gunson BK, Bramhall SB, Mutimer DJ, Neuberger JM, Newsome PN. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? Liver Transpl. 2011;17:1292-1298. [PMID: 21761549 DOI: 10.1002/lt.22382] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
41 Missikpode C, Kramer H, Cotler SJ, Durazo-Arvizu R, Lash JP, Kallwitz E, Cai J, Kuniholm MH, Rosas SE, Ricardo AC, Talavera GA, Raij L, Pirzada A, Daviglus ML. Association of elevated serum aminotransferase levels with chronic kidney disease measures: hispanic community health study/study of latinos. BMC Nephrol 2021;22:302. [PMID: 34493216 DOI: 10.1186/s12882-021-02483-y] [Reference Citation Analysis]
42 Franch-Nadal J, Caballeria L, Mata-Cases M, Mauricio D, Giraldez-García C, Mancera J, Goday A, Mundet-Tudurí X, Regidor E; PREDAPS Study Group. Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study. PLoS One 2018;13:e0198327. [PMID: 29856820 DOI: 10.1371/journal.pone.0198327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
43 Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
44 Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9:372-381. [PMID: 22565095 DOI: 10.1038/nrgastro.2012.79] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
45 Sinclair SH, Schwartz SS. Diabetic Retinopathy-An Underdiagnosed and Undertreated Inflammatory, Neuro-Vascular Complication of Diabetes. Front Endocrinol (Lausanne). 2019;10:843. [PMID: 31920963 DOI: 10.3389/fendo.2019.00843] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
46 Katsiki N, Anagnostis P, Kotsa K, Goulis DG, Mikhailidis DP. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. Curr Pharm Des. 2019;25:2051-2059. [PMID: 31298151 DOI: 10.2174/1381612825666190708192134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
47 Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310. [PMID: 28218263 DOI: 10.1038/nrneph.2017.16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 23.0] [Reference Citation Analysis]
48 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 806] [Article Influence: 95.7] [Reference Citation Analysis]
49 Sung K, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. Journal of Hepatology 2014;60:1040-5. [DOI: 10.1016/j.jhep.2014.01.009] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 10.4] [Reference Citation Analysis]
50 Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? Journal of Hepatology 2011;54:1020-9. [DOI: 10.1016/j.jhep.2010.11.007] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 9.2] [Reference Citation Analysis]
51 Adiga US, Malawadi BN. Association of Diabetic Nephropathy and Liver Disorders. J Clin Diagn Res 2016;10:BC05-7. [PMID: 27891331 DOI: 10.7860/JCDR/2016/21672.8728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
52 Bulum T, Kolarić B, Duvnjak M, Duvnjak L. Alkaline phosphatase is independently associated with renal function in normoalbuminuric type 1 diabetic patients. Ren Fail 2014;36:372-7. [PMID: 24455970 DOI: 10.3109/0886022X.2013.872569] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
53 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59:1121-40. [DOI: 10.1007/s00125-016-3902-y] [Cited by in Crossref: 206] [Cited by in F6Publishing: 186] [Article Influence: 34.3] [Reference Citation Analysis]
54 An JN, Joo SK, Koo BK, Kim JH, Oh S, Kim W. Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease. Hepatol Int 2020;14:798-807. [DOI: 10.1007/s12072-020-10063-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Bhagat N, Zarbin MA. Epidemiology, Risk Factors, and Pathophysiology of Diabetic Retinopathy. In: Bandello F, Zarbin MA, Lattanzio R, Zucchiatti I, editors. Clinical Strategies in the Management of Diabetic Retinopathy. Cham: Springer International Publishing; 2019. pp. 1-19. [DOI: 10.1007/978-3-319-96157-6_1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
56 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 127] [Article Influence: 13.2] [Reference Citation Analysis]
57 Caballeria J, Caballeria L. Esteatohepatitis no alcohólica y diabetes. Endocrinología y Nutrición 2016;63:377-9. [DOI: 10.1016/j.endonu.2016.06.001] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
58 Fante RJ, Gardner TW, Sundstrom JM. Current and future management of diabetic retinopathy: a personalized evidence-based approach. Diabetes Manag (Lond) 2013;3:481-94. [PMID: 24932222 DOI: 10.2217/dmt.13.50] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
59 Mantovani A, Rigolon R, Mingolla L, Pichiri I, Cavalieri V, Salvotelli L, Stoico V, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. Journal of Diabetes and its Complications 2017;31:1021-6. [DOI: 10.1016/j.jdiacomp.2017.01.024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
60 Szczuko M, Kaczkan M, Małgorzewicz S, Rutkowski P, Dębska-Ślizień A, Stachowska E. The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression. Lipids Health Dis 2020;19:77. [PMID: 32303226 DOI: 10.1186/s12944-020-01258-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Wang Y, Yu Y, Wan H, Chen Y, Xia F, Zhang W, Zhang K, Gu X, Zhang Y, Lin Z, Yu Y, Wang N, Lu Y. Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients. Diabetes Metab Res Rev 2020;36:e3294. [PMID: 32017389 DOI: 10.1002/dmrr.3294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Liu XQ, Li YB, Wu L. Effect of Buzhong Yiqi Pill on oxidative damage and glycogen synthesis in the liver of early diabetic rats. Shijie Huaren Xiaohua Zazhi 2012; 20(1): 60-65 [DOI: 10.11569/wcjd.v20.i1.60] [Reference Citation Analysis]
63 Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64:638-652. [PMID: 25085644 DOI: 10.1053/j.ajkd.2014.05.019] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 13.0] [Reference Citation Analysis]
64 Ikewuchi CC, Ikewuchi JC, Ifeanacho MO. Restoration of plasma markers of liver and kidney functions/integrity in alloxan-induced diabetic rabbits by aqueous extract of Pleurotus tuberregium sclerotia. Biomed Pharmacother 2017;95:1809-14. [PMID: 28968925 DOI: 10.1016/j.biopha.2017.09.075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
65 Huh JH, Kim JY, Choi E, Kim JS, Chang Y, Sung KC. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One. 2017;12:e0180951. [PMID: 28738057 DOI: 10.1371/journal.pone.0180951] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
66 Rosato V, Masarone M, Dallio M, Federico A, Aglitti A, Persico M. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. Int J Environ Res Public Health 2019;16:E3415. [PMID: 31540048 DOI: 10.3390/ijerph16183415] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
67 Targher G, Chonchol M, Pichiri I, Zoppini G. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest 2011;34:544-51. [PMID: 21427524 DOI: 10.3275/7614] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
68 Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract 2014;2014:847539. [PMID: 24729784 DOI: 10.1155/2014/847539] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
69 Ahn AL, Choi JK, Kim MN, Kim SA, Oh EJ, Kweon HJ, Cho DY. Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older. Korean J Fam Med. 2013;34:199-205. [PMID: 23730487 DOI: 10.4082/kjfm.2013.34.3.199] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
70 Sirota JC, McFann K, Targher G, Chonchol M, Jalal DI. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol. 2012;36:466-471. [PMID: 23128368 DOI: 10.1159/000343885] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
71 Choe AR, Ryu DR, Kim HY, Lee HA, Lim J, Kim JS, Lee JK, Kim TH, Yoo K. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol 2020;21:50. [PMID: 32066395 DOI: 10.1186/s12882-020-01718-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Dietrich CG, Rau M, Jahn D, Geier A. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. Expert Opin Drug Metab Toxicol 2017;13:625-40. [PMID: 28359183 DOI: 10.1080/17425255.2017.1314461] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
73 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-S64. [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012] [Cited by in Crossref: 1011] [Cited by in F6Publishing: 958] [Article Influence: 168.5] [Reference Citation Analysis]
74 Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E. Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. Diabet Med. 2012;29:220-226. [PMID: 21883436 DOI: 10.1111/j.1464-5491.2011.03427.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
75 DeBoer MD, Filipp SL, Musani SK, Sims M, Okusa MD, Gurka M. Metabolic Syndrome Severity and Risk of CKD and Worsened GFR: The Jackson Heart Study. Kidney Blood Press Res 2018;43:555-67. [PMID: 29642060 DOI: 10.1159/000488829] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
76 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 21.5] [Reference Citation Analysis]
77 Katchman H, Zelber-sagi S, Baruch R, Berman G, Schwartz IF, Schwartz D, Nakache R, Goykhman Y, Katz P, Shibolet O, Shashar M, Grupper A. Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controls. Clin Transplant 2018;32:e13240. [DOI: 10.1111/ctr.13240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol 2020;19:134-44. [PMID: 31606352 DOI: 10.1016/j.aohep.2019.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
79 Regnell SE, Peterson P, Trinh L, Broberg P, Leander P, Lernmark Å, Månsson S, Elding Larsson H. Magnetic resonance imaging reveals altered distribution of hepatic fat in children with type 1 diabetes compared to controls. Metabolism 2015;64:872-8. [PMID: 25982699 DOI: 10.1016/j.metabol.2015.04.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
80 Durand F, Francoz C, Asrani SK, Khemichian S, Pham TA, Sung RS, Genyk YS, Nadim MK. Acute Kidney Injury After Liver Transplantation. Transplantation 2018;102:1636-49. [DOI: 10.1097/tp.0000000000002305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
81 Vendhan R, Amutha A, Anjana RM, Unnikrishnan R, Mohan V. Clinical profile of nonalcoholic Fatty liver disease among young patients with type 1 diabetes mellitus seen at a diabetes speciality center in India. Endocr Pract 2014;20:1249-57. [PMID: 25100370 DOI: 10.4158/EP14044.OR] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
82 Olusanya TO, Lesi OA, Adeyomoye AA, Fasanmade OA. Non alcoholic fatty liver disease in a Nigerian population with type II diabetes mellitus. Pan Afr Med J 2016;24:20. [PMID: 27583084 DOI: 10.11604/pamj.2016.24.20.8181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
83 Barros BSV, Monteiro FC, Terra C, Gomes MB. Prevalence of non-alcoholic fatty liver disease and its associated factors in individuals with type 1 diabetes: a cross-sectional study in a tertiary care center in Brazil. Diabetol Metab Syndr 2021;13:33. [PMID: 33741024 DOI: 10.1186/s13098-021-00649-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol 2021; 27(17): 1864-1882 [PMID: 34007127 DOI: 10.3748/wjg.v27.i17.1864] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Xu X, Lu L, Dong Q, Li X, Zhang N, Xin Y, Xuan S. Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. Lipids Health Dis. 2015;14:158. [PMID: 26631018 DOI: 10.1186/s12944-015-0141-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
86 Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20(26): 8377-8392 [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
87 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402. [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004] [Cited by in Crossref: 1478] [Cited by in F6Publishing: 1378] [Article Influence: 246.3] [Reference Citation Analysis]
88 Harman DJ, Kaye PV, Harris R, Suzuki A, Gazis A, Aithal GP. Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes. Hepatology 2014;60:158-68. [DOI: 10.1002/hep.27098] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
89 Khneizer G, Rizvi S, Gawrieh S. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Adv Exp Med Biol 2021;1307:417-40. [PMID: 32424494 DOI: 10.1007/5584_2020_532] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]